home > epc > autumn 2014 > breaking news
European Pharmaceutical Contractor

Breaking News

Two items in the newspaper on 26 July caught my attention. The first article’s headline read “Cancer experts unite against EU data law”, and discussed the proposed EU General Data Protection Regulation which would – according to the report – require doctors across Europe to obtain explicit and specific patient consent every time they wished to use their data. Seemingly, this means that any patient could give consent to personal data usage in one trial, but if this data were to be used in further studies, specific permission would have to be provided again.

At present, patients can give permission in perpetuity so that comparison studies using the same data can be carried out. However, the planned new restriction will prevent such studies, especially Cochrane trials, from being conducted unless consent is given by every patient – alive or deceased.

Although the proposed regulation makes no specific mention of cancer studies, the follow-up of patients would – argues the European Society of Medical Oncology – prove very difficult, if not impossible, and would put a halt to many public health research efforts. The draft regulation has been available for over two years and, clearly, the efforts of cancer researchers have been inadequate to persuade the European Parliament that the planned legislation is misguided. Nevertheless, the regulation was approved by the Parliament by a huge majority, and it may prove too late to change this outcome in the near future (also see page 28).

The second item, entitled “Google sets its sights on early detection of deadly diseases”, reported that Google is to collect samples of human tissue from thousands of people to potentially detect the earliest signs of cancer and other fatal diseases. The study will also take blood, urine, saliva and DNA samples from test subjects in order to determine what comprises a healthy human being; the objective being to detect a biomarker that will predict the onset of diseases.

Google’s mission statement is to “organise the world’s information and make it universally acceptable and useful”. If the EU General Data Protection Regulation is not amended, then this objective will surely be seriously compromised and not applicable to the EU. Google has already shown the power of its algorithms in detecting changes in human behaviour through its study of the transmission of avian flu in the US. Here, the company was able to predict outbreaks two or three weeks prior to the estimations made by the Centers for Disease Control and Prevention, by analysing search patterns on the Google search engine. Restriction on its activities in the public health area may have a significant impact in Europe.

As I looked through my particular newspaper over the entire week, I also noticed a discouraging pattern. The business section summarising the main events of the previous day had no mention of any noteworthy healthcare-related topics.

Given the interest of the general public in their health, this seemed to be a surprising omission. The one reference that was made during the week, was the announcement of the submission for the malaria vaccine registration from GlaxoSmithKline. The company – currently under considerable financial pressure due to falling sales and scandals in China – is receiving little credit for its altruistic development of this vaccine.

This tends to confirm my view that the pharmaceutical industry is currently a media scapegoat, whatever its achievements. For example, the BBC recently reported on an ongoing prostate cancer study that was being carried out with thousands of patients worldwide, and seemed to imply that this was being financed by Cancer Research UK, rather than a pharma company. Perhaps the industry feels that, at the present time, a low profile is for the best.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its dual-terminal operations seamlessly

Completing the gradual transition process to Istanbul Airport, one of the largest airports of the world, the global air cargo brand Turkish Cargo maintains its dual-terminal operations with full capacity on 7/24 basis without any sales restriction.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement